Home Cart Sign in  
Chemical Structure| 1125758-85-1 Chemical Structure| 1125758-85-1

Structure of A-804598
CAS No.: 1125758-85-1

Chemical Structure| 1125758-85-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

A-804598 is a CNS-permeable, competitive, and selective P2X7 receptor antagonist with high affinity for mouse, rat, and human P2X7 receptors, with IC50 values of 9 nM, 10 nM, and 11 nM, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of A-804598

CAS No. :1125758-85-1
Formula : C19H17N5
M.W : 315.37
SMILES Code : C[C@H](N/C(NC1=C2C=CC=NC2=CC=C1)=N/C#N)C3=CC=CC=C3
MDL No. :MFCD22683834
InChI Key :PQYCRDPLPKGSME-AWEZNQCLSA-N
Pubchem ID :53325874

Safety of A-804598

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Primary microglia from SOD1-G93A mice 10 μM 15 minutes To investigate the effect of P2X7 activation on the expression of the autophagic marker LC3B-II in SOD1-G93A microglia. Results show that P2X7 activation significantly increases LC3B-II expression, and this effect is inhibited by the P2X7 antagonist A-804598. PMC5566572
Microglia 10 µM 30 minutes To investigate the effects of A-804598 on microglial morphology and cytokine secretion. Results showed that A-804598 reduced the proportion of round/ameboid microglia and increased complex morphologies, while also decreasing pro-inflammatory cytokine levels (e.g., IL-1β, IL-6, and TNFα) and increasing anti-inflammatory cytokine IL-4 secretion. PMC10123291
Neuronal and non-neuronal cells in trigeminal ganglion cultures 100 nM 15 min To investigate the effect of A-804598 on BzATP-induced membrane pore permeability. Results showed that A-804598 significantly reduced the BzATP-evoked fluorescence signal and the number of responding cells in R192Q KI cultures. PMC5714839
J774 macrophages 10 μM 15 minutes To assess the effect of A-804598 on ATP-induced ethidium+ uptake, results showed A-804598 near-completely abrogated ATP-induced ethidium+ uptake PMC5714832
Retinal ganglion cells 30 μM 10 minutes To investigate the effect of P2X7 receptor antagonist A804598 on BzATP-induced suppression of RGC ON-fEPSP, results showed that A804598 significantly attenuated the inhibitory effect of BzATP. PMC5123999

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Chronic intragastric ethanol infusion and high-fat diet (Hybrid) model Intragastric administration 5 mg/kg 3 times a week for 3 weeks A804598 reversed the changes in microglia and astrocytes, reduced/abolished increases in mRNA levels of inflammatory markers including IL-1β, iNOS, CXCR2, and components of inflammatory signaling pathways such as TLR2, CASP1, NF-kB1, and CREB1, as well as protein levels of pro-IL-1β and Nf-kB1. The P2X7R antagonist did not affect the increase in mRNA levels of fractalkine (CX3CL1) and its receptor CX3CR1, an interaction that plays a neuroprotective role in neuron-glia communication. P2X7R antagonism also resulted in reduction of inflammatory markers but did not alter liver steatosis. PMC6494709
SOD1-G93A transgenic mice ALS mouse model Intraperitoneal injection 30 mg/kg Five times a week until end stage of disease To evaluate the effect of the P2X7 antagonist A-804598 on the expression of the autophagic marker SQSTM1/p62 in the lumbar spinal cord of SOD1-G93A mice. Results show that A-804598 treatment significantly decreases SQSTM1/p62 expression but has no significant effect on disease progression and survival. PMC5566572
Sprague-Dawley rats High-fat diet induced anxiety and anhedonia model Intraperitoneal injection 5 mg/kg Twice daily for 25 days To investigate the reversal effect of P2X7 receptor antagonist A804598 on high-fat diet-induced anxiety behaviors. Results showed that A804598 significantly reduced anxiety behaviors in high-fat diet rats in the open field test and elevated plus maze. PMC4869056
Sprague-Dawley rats Traumatic brain injury model Intraperitoneal injection 10 mg/kg Once daily for 5 consecutive days A804598 reduced the number of MV-like particles released by microglial cells after traumatic brain injury, reduced neuronal apoptosis, increased neuronal survival, and improved neurobehavioral outcomes PMC5714842
BALB/c mice IMQ-induced psoriasis-like inflammation model Intraperitoneal injection 50 mg/kg Injected every second day (days 0 and 2) To evaluate the effect of A-804598 on IMQ-induced psoriasis-like inflammation, results showed A-804598 had no significant effect on ear swelling and skin pathology PMC5714832
Mice Ex vivo retinal whole mount preparation Perfusion 30 μM Single administration, lasting 10 minutes To investigate the effect of P2X7 receptor antagonist A804598 on BzATP-induced suppression of RGC ON-fEPSP, results showed that A804598 significantly attenuated the inhibitory effect of BzATP. PMC5123999

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.17mL

0.63mL

0.32mL

15.85mL

3.17mL

1.59mL

31.71mL

6.34mL

3.17mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories